NZ598242A - Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer - Google Patents

Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer

Info

Publication number
NZ598242A
NZ598242A NZ598242A NZ59824210A NZ598242A NZ 598242 A NZ598242 A NZ 598242A NZ 598242 A NZ598242 A NZ 598242A NZ 59824210 A NZ59824210 A NZ 59824210A NZ 598242 A NZ598242 A NZ 598242A
Authority
NZ
New Zealand
Prior art keywords
erythropoietin production
compound
prolyl hydroxylase
action
hydroxylase inhibitor
Prior art date
Application number
NZ598242A
Other languages
English (en)
Inventor
Takuya Matsui
Yosuke Ogoshi
Masahiro Yokota
Masakazu Terashita
Ikuo Mitani
Takahiro Hotta
Dai Motoda
Hiroyuki Abe
Kazuhito Ueyama
Takashi Ito
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NZ598242A publication Critical patent/NZ598242A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
NZ598242A 2009-07-17 2010-07-16 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer NZ598242A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17
US27312709P 2009-07-30 2009-07-30
PCT/JP2010/062037 WO2011007856A1 (ja) 2009-07-17 2010-07-16 トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用

Publications (1)

Publication Number Publication Date
NZ598242A true NZ598242A (en) 2013-09-27

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598242A NZ598242A (en) 2009-07-17 2010-07-16 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer

Country Status (28)

Country Link
US (3) US8283465B2 (https=)
EP (3) EP3594213A1 (https=)
JP (9) JP5021797B2 (https=)
KR (5) KR101850661B1 (https=)
CN (1) CN102471337B (https=)
AR (1) AR077417A1 (https=)
AU (1) AU2010271732B2 (https=)
BR (1) BR112012001157A2 (https=)
CA (1) CA2768505C (https=)
CO (1) CO6430426A2 (https=)
DK (1) DK2455381T5 (https=)
ES (1) ES2477968T3 (https=)
HR (1) HRP20140705T1 (https=)
IL (1) IL217541A (https=)
ME (1) ME01858B (https=)
MX (1) MX2012000766A (https=)
MY (1) MY160814A (https=)
NZ (1) NZ598242A (https=)
PE (1) PE20120629A1 (https=)
PL (1) PL2455381T3 (https=)
PT (1) PT2455381E (https=)
RS (1) RS53499B1 (https=)
RU (1) RU2538963C2 (https=)
SG (1) SG178049A1 (https=)
SI (1) SI2455381T1 (https=)
SM (1) SMT201500122B (https=)
TW (1) TWI485150B (https=)
WO (1) WO2011007856A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN104936591B (zh) 2012-11-26 2018-05-29 国立大学法人东北大学 促红细胞生成素表达增强剂
JO3781B1 (ar) 2012-12-24 2021-01-31 Cadila Healthcare Ltd مشتقات الكينولون
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
SG11201602572YA (en) * 2013-10-03 2016-04-28 Kura Oncology Inc Inhibitors of erk and methods of use
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
EP4667059A3 (en) 2015-05-28 2026-04-08 Japan Tobacco Inc. Method for treating or preventing diabetic nephropathy
KR102523786B1 (ko) * 2016-11-25 2023-04-20 니뽄 다바코 산교 가부시키가이샤 트리아졸로피리딘 화합물의 제조 방법
CA3062972C (en) * 2017-05-09 2021-09-14 Kind Pharmaceutical Indolizine derivatives and their application in medicine
KR20200064101A (ko) * 2017-10-04 2020-06-05 니뽄 다바코 산교 가부시키가이샤 질소 함유 헤테로아릴 화합물 및 그의 의약 용도
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
CA3106385A1 (en) 2018-09-13 2020-03-19 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法
KR20220152276A (ko) * 2020-03-11 2022-11-15 깃세이 야쿠힌 고교 가부시키가이샤 이미다조피리디논 화합물 또는 그 염의 결정
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
EP4308120A4 (en) 2021-03-19 2024-11-27 Zydus Lifesciences Limited TREATMENT OF SICKLE CELL ANEMIA
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN116496269B (zh) * 2021-12-02 2025-02-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
CN117327066A (zh) * 2022-06-30 2024-01-02 上海济煜医药科技有限公司 一种新多晶型、其制备方法及其用于制备药物的用途
JP2025529533A (ja) * 2022-09-19 2025-09-04 蘇中薬業集団股▲ふん▼有限公司 プロリルヒドロキシラーゼ阻害剤およびその用途
TWI905781B (zh) * 2023-06-02 2025-11-21 大陸商蘇中藥業集團股份有限公司 脯胺醯羥化酶抑制劑及其用途
TW202506675A (zh) * 2023-08-08 2025-02-16 美商富曼西公司 用於防治和對抗無脊椎有害生物的連接的雙環化合物
WO2025087207A1 (zh) 2023-10-24 2025-05-01 杭州安道药业有限公司 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用
TW202529740A (zh) * 2023-12-19 2025-08-01 美商阿克比治療有限公司 Ｐｈｄ抑制劑化合物、組成物及使用方法
WO2025167738A1 (zh) * 2024-02-05 2025-08-14 深圳信立泰药业股份有限公司 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用
CN119700755B (zh) * 2024-02-05 2026-01-30 深圳信立泰药业股份有限公司 化合物在制备预防和/或治疗高原病的药物中的应用
CN119039291A (zh) * 2024-09-09 2024-11-29 南京药坦生物科技有限公司 一种恩那度司他中间体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
MXPA04003277A (es) * 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
AU2005268893B2 (en) * 2004-08-05 2011-10-13 F. Hoffmann-La Roche Ag Indole, indazole or indoline derivatives
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
PL3357911T3 (pl) * 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
EP2155746A2 (en) 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
JP5408434B2 (ja) 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
EA201000915A1 (ru) * 2007-11-30 2011-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы пролилгидроксилазы
JP2011505367A (ja) * 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
US8324241B2 (en) * 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
US20110039895A1 (en) * 2008-04-30 2011-02-17 Glaxo Smith Kline LLC., a corporation Prolyl hydroxylase inhibitors
WO2009146358A1 (en) 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
HRP20160488T1 (hr) 2008-12-19 2016-06-17 Leo Pharma A/S Triazolopiridini kao inhibitori fosfodiesteraze za liječenje kožnih bolesti
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers

Also Published As

Publication number Publication date
DK2455381T5 (en) 2015-02-09
JP2012144571A (ja) 2012-08-02
EP3594213A1 (en) 2020-01-15
HK1168346A1 (en) 2012-12-28
JP5021797B2 (ja) 2012-09-12
US20130096155A1 (en) 2013-04-18
JP2017214404A (ja) 2017-12-07
EP2455381B9 (en) 2014-10-22
ES2477968T3 (es) 2014-07-18
KR20180042443A (ko) 2018-04-25
AU2010271732A1 (en) 2012-03-08
KR20170018105A (ko) 2017-02-15
WO2011007856A1 (ja) 2011-01-20
SMT201500122B (it) 2015-07-09
IL217541A0 (en) 2012-02-29
TWI485150B (zh) 2015-05-21
AU2010271732B2 (en) 2016-08-25
JP2019019144A (ja) 2019-02-07
JP2015003933A (ja) 2015-01-08
AR077417A1 (es) 2011-08-24
ME01858B (me) 2014-12-20
JP2011037841A (ja) 2011-02-24
IL217541A (en) 2014-07-31
JP2022126843A (ja) 2022-08-30
CO6430426A2 (es) 2012-04-30
KR101706803B1 (ko) 2017-02-14
PE20120629A1 (es) 2012-05-30
TW201105671A (en) 2011-02-16
CA2768505C (en) 2018-06-12
US20110077267A1 (en) 2011-03-31
RS53499B1 (sr) 2015-02-27
KR101850661B1 (ko) 2018-04-19
KR20230165366A (ko) 2023-12-05
KR20260012830A (ko) 2026-01-27
PL2455381T3 (pl) 2014-10-31
BR112012001157A2 (pt) 2016-02-23
MX2012000766A (es) 2012-02-08
JP2024091878A (ja) 2024-07-05
CN102471337B (zh) 2014-12-10
JP6434575B2 (ja) 2018-12-05
CN102471337A (zh) 2012-05-23
US8283465B2 (en) 2012-10-09
HRP20140705T1 (hr) 2014-09-12
EP2455381A4 (en) 2012-12-12
JP2020111612A (ja) 2020-07-27
CA2768505A1 (en) 2011-01-20
KR20120051704A (ko) 2012-05-22
PT2455381E (pt) 2014-06-24
MY160814A (en) 2017-03-31
EP2455381B1 (en) 2014-05-28
SI2455381T1 (sl) 2014-08-29
RU2538963C2 (ru) 2015-01-10
DK2455381T3 (da) 2014-07-21
EP2455381A1 (en) 2012-05-23
EP2746282A1 (en) 2014-06-25
RU2012105467A (ru) 2013-08-27
US20160145254A1 (en) 2016-05-26
JP2016040321A (ja) 2016-03-24
SG178049A1 (en) 2012-03-29
ES2477968T9 (es) 2014-11-13

Similar Documents

Publication Publication Date Title
NZ598242A (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
WO2008011130A8 (en) Amide compounds
WO2008011131A3 (en) Amide compounds
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
GEP20125635B (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
SG11201408052WA (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
TW200728307A (en) Novel spirochromanone derivatives
AU2012214029A8 (en) Rorgammat inhibitors
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
IN2012DN01273A (https=)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 JUL 2017 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20140402

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2018 BY CPA GLOBAL

Effective date: 20170601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2019 BY CPA GLOBAL

Effective date: 20180531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2020 BY CPA GLOBAL

Effective date: 20190530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2021 BY CPA GLOBAL

Effective date: 20200604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2022 BY CPA GLOBAL

Effective date: 20210603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2023 BY CPA GLOBAL

Effective date: 20220607

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2024 BY CPA GLOBAL

Effective date: 20230601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250529